SCHEMBL6058588

SCHEMBL6058588

O=Cc1cc(Cl)c(-c2ccc(OCc3ccccc3)cc2)c2ccccc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSTP1 P09211 2/20 0.48
MAOA P21397 2/20 0.44
MAOB P27338 2/20 0.44
PTPN1 P18031 1/20 0.43
PRMT5 O14744 1/20 0.42
NR1H2 P55055 1/20 0.42
MCL1 Q07820 2/20 0.41
BCHE P06276 1/20 0.41
LMNA P02545 1/20 0.41
CYP1A2 P05177 1/20 0.41
PTGS1 P23219 1/20 0.41
SLC6A2 P23975 1/20 0.41
CYP2C19 P33261 1/20 0.41
PTGS2 P35354 1/20 0.41
SLC6A3 Q01959 1/20 0.41
HIF1A Q16665 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
NR4A1 P22736 1/20 0.40
NR4A2 P43354 1/20 0.40
NR4A3 Q92570 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6058584 0.82 MAOA (0.55) GSTP1MAOAMAOBPTPN1PRMT5
SCHEMBL6058772 0.78 ERN1 (0.39) PTPN1MCL1
SCHEMBL30662424 0.76 LMNA (0.58) GSTP1MAOAMAOBBCHELMNA
SCHEMBL6059192 0.76 GSTP1 (0.51) GSTP1MAOAMAOBMCL1BCHE
SCHEMBL190184 0.76 HPGD (0.58) MAOAMAOBMEN1NPC1RAB9A
SCHEMBL4079311 0.76 MAOA (0.56) GSTP1MAOAMAOBBCHEMEN1
SCHEMBL30402795 0.76 MAOA (0.56) GSTP1MAOAMAOBBCHEMEN1
SCHEMBL6058541 0.75 MGAM (0.51) GSTP1MAOAMAOBPRMT5CYP1A2
SCHEMBL6704971 0.74 MEN1 (0.49) PTPN1HIF1AMEN1KMT2ABCL2L1
SCHEMBL6059075 0.74 GSTP1 (0.55) GSTP1MAOAMAOBPRMT5MCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0877607-B1 BIPHENYL COMPOUNDS AND USE THEREOF AS OESTROGENIC AGENTS AVENTIS PHARMA SA (FR) 2006-11-15 EP disclosed
US-6794415-B2 Biphenyl compounds and their use as oestrogenic agents AVENTIS PHARMA S.A. (FR) 2004-09-21 US disclosed
US-20040043993-A1 Biphenyl compounds and their use as oestrogenic agents AVENTIS PHARMA S.A. 2004-03-04 US disclosed
US-6563008-B2 Treatment of disorders linked to hypofolliculinemia and of certain estrogen-dependent pathologies such as prostatic adenomas or carcinomas, and of benign tumours of the breast AVENTIS PHARMA S.A. (FR) 2003-05-13 US disclosed
US-20020068736-A1 Biphenyl compounds and their use as oestrogenic agents LESUISSE DOMINIQUE (FR) 2002-06-06 US disclosed
US-6288126-B1 Biphenyl compounds and use thereof as oestrogenic agents AVENTIS PHARMA S.A. 2001-09-11 US disclosed
EP-0877607-A1 BIPHENYL COMPOUNDS AND USE THEREOF AS OESTROGENIC AGENTS HOECHST MARION ROUSSEL (FR) 1998-11-18 EP disclosed
WO-1997027846-A1 BIPHENYL COMPOUNDS AND USE THEREOF AS OESTROGENIC AGENTS HOECHST MARION ROUSSEL (FR) 1997-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020068736-A1 Biphenyl compounds and their use as oestrogenic agents ESR2, ESR1, CYP19A1 GSTP1 564/4885MAOA 1209/4885MAOB 507/4885
US-20040043993-A1 Biphenyl compounds and their use as oestrogenic agents CYP19A1, HSD17B11, GPER1 GSTP1 389/4885MAOA 433/4885MAOB 419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.